Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic LeukemiaAndy C. Rawstron, Peter Hillmen, Fiona Bennett et al.|New England Journal of Medicine|2008Cited by 605
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX StudyAndy C. Rawstron, Roger G. Owen, Graham Jackson et al.|Journal of Clinical Oncology|2013Cited by 419
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, David A. Cairns et al.|New England Journal of Medicine|2023Cited by 155
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Sean Girvan et al.|New England Journal of Medicine|2025Cited by 26
Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib ExposureAndy C. Rawstron, Peter Hillmen, Talha Munir et al.|Blood|2018Cited by 7